Sponsored by
This article contains inaccuracies. Temodar was initially approved for recurrent anaplastic astrocytoma in 1999, not for glioblastoma as stated. The FDA declined the request to approve it for glioblastoma at that time. It wasn't until 2005 that the FDA extended its approval to include newly diagnosed glioblastoma. The most recent update added approval for newly diagnosed anaplastic astrocytoma.